Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 studyMarina Cuchel, Daniel J. Rader, Cesare R. Sirtori et al.|The Lancet|2012Cited by 739
From Vulnerable Plaque to Vulnerable Patient—Part III: Executive Summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force ReportMorteza Naghavi, Prediman K. Shah, Erling Falk et al.|The American Journal of Cardiology|2006Cited by 635
ANGPTL3 Inhibition in Homozygous Familial HypercholesterolemiaDaniel Gaudet, G. Kees Hovingh, Daniel A. Gipe et al.|New England Journal of Medicine|2017Cited by 329
Faculty Opinions recommendation of CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis.Prediman K. Shah|Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature|2019Cited by 0